LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

LLY

1,142.76

+2.44%↑

JNJ

229.74

+1.49%↑

ABBV

228.33

+3.53%↑

UNH

398.27

-0.2%↓

MRK

120.71

+1.56%↑

Home・Stock List・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Open

SectorHealthcare

88.56 3.54

Buy Sell

Overview

Share price change

24h

Current

Min

85.83

Max

88.93

Key metrics
By Trading Economics
Income	-8.1M -56M
Sales	2.9M 60M
EPS	-0.83
Profit margin	-92.559
Employees	414
EBITDA	-9.7M -52M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+61.46% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-96M 5.8B
Previous open	85.02
Previous close	88.56

News Sentiment

By Acuity

50%

155 / 344 Healthcare

Rhythm Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jun 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 Jun 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 Jun 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 Jun 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 Jun 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 Jun 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 Jun 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Jun 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 Jun 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 Jun 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 Jun 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 Jun 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 Jun 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 Jun 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 Jun 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 Jun 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 Jun 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 Jun 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 Jun 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 Jun 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 Jun 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 Jun 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 Jun 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 Jun 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 Jun 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 Jun 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Rhythm Pharmaceuticals Inc Forecast

Price Target

By TipRanks

61.46% upside

12 Months Forecast

Average 136.77 USD 61.46%

High 158 USD

Low 105 USD

Based on 14 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Rhythm Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

155 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.